Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 May 24;7(21):30032-6.
doi: 10.18632/oncotarget.9090.

Effects of aging on the effectiveness of smoking cessation medication

Jaqueline Scholz  1 , Paulo Caleb Junior Lima Santos  2 , Carolina Giusti Buzo  3 , Neuza Helena Moreira Lopes  3   4 , Tania Ogawa Abe  1 , Patricia Viviane Gaya  1 , Humberto Pierri  3 , Clarice Amorim  5 , Alexandre Costa Pereira  2
Affiliations
Comparative Study

Effects of aging on the effectiveness of smoking cessation medication

Jaqueline Scholz et al. Oncotarget. .

Abstract

Background: Considering the pharmacokinetic and pharmacodynamic aspects of different medications, it is plausible that the age of a smoker could affect the half-life of these drugs. The aim of this study was to compare the effectiveness of smoking cessation drugs (nicotine replacement therapy, bupropion, and varenicline) used either in isolation or in combination in adults under and over 60 years of age.

Methods: Data were collected from 940 Brazilian patients participating in a smoking cessation program. Participants were prescribed smoking cessation medication to be used for at least 12 weeks and were followed for 52 weeks.

Results: Cessation rates were significantly different among younger and older participants who were using nicotine replacement therapy (NRT) alone. Being over 60 years of age was significantly associated with increased cessation success among those who used NRT alone (OR 2.34, 95% CI: 1.36 to 4.04, p = 0.002). The effectiveness of varenicline and bupropion were not significantly different according to age groups.

Conclusion: Using age as a predictor for tailoring smoking cessation drugs might potentially lead to a more individualized prescription of smoking cessation therapy. These results should be tested in randomized controlled trials.

Keywords: Gerotarget; aging; bupropion; nicotine replacement therapy; smoking cessation; varenicline.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTERESTS J. Scholz is the principal site investigator in Varenicline Trials sponsored by Pfizer. Other authors declare that they have no competing interests.

References

    1. Beaglehole R, Bonita R, Horton R, Adams C, Alleyne G, Asaria P, Baugh V, Bekedam H, Billo N, Casswell S, Cecchini M, Colagiuri R, Colagiuri S, et al. Priority actions for the non-commuunicable disease crisis. Lancet. 2011;377:1438–47. - PubMed
    1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, et al. Resistant hypertension: diagnosis, evaluation, and treatment. Hypertension. 2008;51:1403–19. - PubMed
    1. Glantz S, Gonzalez M. Effective tobacco control is key to rapid progress in reduction of non-communicable diseases. Lancet. 2012;379:1269–71. - PMC - PubMed
    1. U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Department of Health and Human Services Centers; Atlanta: Available at: http://www.surgeongeneral.gov/library/reports/50-years-of-progress/. Published February 7, 2014.
    1. World Health Organization . Report on the global tobacco epidemic 2009: implementing smoke-free environments. Geneva: WHO Pevent of Noncommunicable Diseases; 2009. http://www.who.int/tobacco/about/en/. Published July 12, 2009.

Publication types

MeSH terms